Oct 06, 2017 9:00 am EDT Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
Oct 04, 2017 7:00 am EDT Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
Sep 26, 2017 7:00 am EDT Capricor Therapeutics Advances Clinical Development Program in Duchenne Muscular Dystrophy with Naming of Principal Investigator
Sep 18, 2017 7:00 am EDT Capricor Therapeutics to Present Six-Month Results from the Randomized HOPE Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
Aug 10, 2017 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 03, 2017 4:05 pm EDT Capricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10
Jul 27, 2017 6:00 am EDT Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
Jul 18, 2017 8:00 am EDT Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
Jul 06, 2017 6:30 pm EDT Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
Jun 29, 2017 9:00 am EDT Six-Month Results from Capricor's HOPE-Duchenne Trial to be Presented at the 2017 PPMD Annual Connect Conference